Singapore’s Aslan Pharma lines up an $86M IPO to fund pivotal cancer drug studies
With its lead oncology drug in a pivotal study for biliary tract cancer and a slate of key catalysts coming up in other trials, Singapore …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
